Literature DB >> 22619094

Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations.

Cristina López1, Julio Delgado, Dolors Costa, Laura Conde, Gabriela Ghita, Neus Villamor, Alba Navarro, Maite Cazorla, Cándida Gómez, Amparo Arias, Concha Muñoz, Tycho Baumann, María Rozman, Marta Aymerich, Dolors Colomer, Francesc Cobo, Elías Campo, Armando López-Guillermo, Emili Montserrat, Ana Carrió.   

Abstract

Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults in Western countries. Chromosomal abnormalities commonly found using conventional cytogenetics and FISH are del(11)(q22-23), trisomy 12, del(13)(q14), and del(17)(p13). Trisomy 12 is the most frequent numerical abnormality in CLL. It can appear isolated or associated with other chromosomal aberrations, including t(14;18)(q32;q21) and trisomy 18. The aim of this study was to determine whether CLL patients with isolated trisomy 12 or associated with other chromosomal alterations have different clinico-pathological features, including a different distribution NOTCH1 mutation. Patients were classified into four groups: Group 1, isolated trisomy 12 (n=14); Group 2, trisomy 12 plus trisomy 18 (n=4); Group 3, trisomy 12 plus t(14;18) (n=8); and Group 4: patients with trisomy 12 plus other abnormalities not involving BCL2 (n=28). The Binet stage and expression of ZAP70 were significantly different among cytogenetic groups. NOTCH1 mutations were detected in 6/12 (50%) patients from Group 1, 4/25 (16%) patients from Group 4, and in no patient from groups 2 and 3 (P=0.020). Patients in Group 2 had a more rapid disease progression (median Treatment-free Survival 2 months) as against patients from Groups 1 (50 months), 3 (69 months), or 4 (68 months; P=0.001). These findings indicate that the distribution of NOTCH1 mutations in CLL with trisomy 12 is heterogeneous and that the presence of additional chromosomal abnormalities such as trisomy 18 could change the prognosis of these patients.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22619094     DOI: 10.1002/gcc.21972

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  21 in total

1.  A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemia.

Authors:  P Sportoletti; S Baldoni; B Del Papa; P Aureli; E Dorillo; L Ruggeri; S Plebani; V Amico; A Di Tommaso; E Rosati; P Marconi; M Di Ianni; F Falzetti
Journal:  Leukemia       Date:  2013-10-09       Impact factor: 11.528

Review 2.  Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution.

Authors:  Lesley-Ann Sutton; Richard Rosenquist
Journal:  Haematologica       Date:  2015-01       Impact factor: 9.941

3.  Clinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia?

Authors:  Reem Alsolami; Samantha Jl Knight; Anna Schuh
Journal:  Per Med       Date:  2013-06-01       Impact factor: 2.512

Review 4.  Mature lymphoid malignancies: origin, stem cells, and chronicity.

Authors:  Simon Husby; Kirsten Grønbæk
Journal:  Blood Adv       Date:  2017-11-28

5.  Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia.

Authors:  Paolo Strati; Lynne V Abruzzo; William G Wierda; Susan O'Brien; Alessandra Ferrajoli; Michael J Keating
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-02-11

Review 6.  The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia.

Authors:  S N Malek
Journal:  Oncogene       Date:  2012-09-24       Impact factor: 9.867

7.  Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation.

Authors:  Sunita R Setlur; Jennifer R Brown; Lijian Yu; Haesook T Kim; Siddha Kasar; Parul Benien; Wei Du; Kevin Hoang; Andrew Aw; Bethany Tesar; Reina Improgo; Stacey Fernandes; Saranya Radhakrishnan; Josephine Klitgaard; Charles Lee; Gad Getz
Journal:  Clin Cancer Res       Date:  2016-08-08       Impact factor: 12.531

Review 8.  Clinical implications of the molecular genetics of chronic lymphocytic leukemia.

Authors:  Robin Foà; Ilaria Del Giudice; Anna Guarini; Davide Rossi; Gianluca Gaidano
Journal:  Haematologica       Date:  2013-05       Impact factor: 9.941

9.  Recurrent mutations refine prognosis in chronic lymphocytic leukemia.

Authors:  P Baliakas; A Hadzidimitriou; L-A Sutton; D Rossi; E Minga; N Villamor; M Larrayoz; J Kminkova; A Agathangelidis; Z Davis; E Tausch; E Stalika; B Kantorova; L Mansouri; L Scarfò; D Cortese; V Navrkalova; M J J Rose-Zerilli; K E Smedby; G Juliusson; A Anagnostopoulos; A M Makris; A Navarro; J Delgado; D Oscier; C Belessi; S Stilgenbauer; P Ghia; S Pospisilova; G Gaidano; E Campo; J C Strefford; K Stamatopoulos; R Rosenquist
Journal:  Leukemia       Date:  2014-06-19       Impact factor: 11.528

Review 10.  The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment.

Authors:  Claudia Pérez-Carretero; Isabel González-Gascón-Y-Marín; Ana E Rodríguez-Vicente; Miguel Quijada-Álamo; José-Ángel Hernández-Rivas; María Hernández-Sánchez; Jesús María Hernández-Rivas
Journal:  Diagnostics (Basel)       Date:  2021-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.